Giorgio Fuiano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giorgio Fuiano has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
G Conte
9 shared publicationsV E Andreucci
8 shared publicationsM Sabbatini
7 shared publicationsD Russo
4 shared publicationsP Stanziale
4 shared publicationsA Dal Canton
3 shared publications
Latest Publications
- 26 June 2009
- Vol. 26 (3) , 372-6
[Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].
Secondary hyperparathyroidism is a frequent complication of chronic renal failure that can induce severe bone disease and negatively influence the cardiovascular outcome. Therefore, nephrologists should attempt to reach the targets recommended by national and international guidelines using all the available therapeutic strategies. We describe the case of a 37-year-old woman affected by spina bifida and myelomeningocele who had been on hemodialysis since 1993. In July 2006 she developed secondary hyperparathyroidism complicated by peritrochanteric calcifications which did not respond to standard therapy. Because it was impossible to perform a parathyroidectomy, we started medical therapy with a combination of sevelamer hydrochloride, paracalcitol and cinacalcet, which resulted in progressive improvement of laboratory data and osteodystrophy. A diagnosis of mixed secondarytertiary hyperparathyroidism was made, but a progressive increase in iPTH to very high levels suggested a rapid evolution toward a pure tertiary form.
- 26 June 2009
- Vol. 26 (3) , 372-6
[Multiple peritrochanteric and pubic calcifications in a young woman on hemodialysis with severe renal osteodystrophy successfully treated with sevelamer+cinacalcet+paracalcitol combination therapy].
Secondary hyperparathyroidism is a frequent complication of chronic renal failure that can induce severe bone disease and negatively influence the cardiovascular outcome. Therefore, nephrologists should attempt to reach the targets recommended by national and international guidelines using all the available therapeutic strategies. We describe the case of a 37-year-old woman affected by spina bifida and myelomeningocele who had been on hemodialysis since 1993. In July 2006 she developed secondary hyperparathyroidism complicated by peritrochanteric calcifications which did not respond to standard therapy. Because it was impossible to perform a parathyroidectomy, we started medical therapy with a combination of sevelamer hydrochloride, paracalcitol and cinacalcet, which resulted in progressive improvement of laboratory data and osteodystrophy. A diagnosis of mixed secondarytertiary hyperparathyroidism was made, but a progressive increase in iPTH to very high levels suggested a rapid evolution toward a pure tertiary form.
- 1 March 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 35 (3) , 448-457
Current indications for renal biopsy: A questionnaire-based survey
- 1 March 2000
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 35 (3) , 448-457
Current indications for renal biopsy: A questionnaire-based survey
- 1 May 1998
- Vol. 66, S91-5
Role of renal biopsy in the diagnosis and prognosis of acute renal failure.
- 1 May 1998
- Vol. 66, S91-5
Role of renal biopsy in the diagnosis and prognosis of acute renal failure.
- 1 June 1997
- Vol. 59, S28-32
Physiologic role and diuretic efficacy of atrial natriuretic peptide in health and chronic renal disease.
In recent years, different clinical studies have provided new information on the pathophysiological role and diuretic effectiveness of atrial natriuretic peptide (ANP) in subjects with normal renal function and patients with chronic renal disease. Plasma ANP (pANP) was increased by infusion at the lowest doses ever tested in humans who were on low salt diet to the levels that the same subjects gained when on a normal salt diet; ANP accounted for at least 40% of the increase of natriuresis. Similarly, ANP appeared to be mainly involved in the physiological down-regulation of salt excretion (that is, during the shift from a normal to low-sodium diet). Interestingly, data have been also attained on the efficacy of ANP as diuretic agent when administered at a low nonhypotensive dosage in normals as well as CRF patients. Indeed, low-dose ANP promoted a marked increase of sodium excretion in CRF patients to the same levels observed in normals, likely because the renal patients exhibited a more marked pANP increment secondary to the lower renal catabolism of the infused hormone. Moreover, aldosterone suppression was greater in CRF patients with respect to normals. Furthermore, the fractional urinary excretion of cGMP increased more in CRF patients than in normals. Finally, ANP infusion augmented the urinary losses of the main solutes retained in CRF (urea, potassium, phosphorous) with a significant decrease in the plasma levels. Hence, ANP per se not only plays a significant role in the up- and down-regulation of sodium excretion in healthy state and chronic renal disease, but it may also be considered to be a powerful and unique diuretic agent in CRF at nonhypotensive dosages.
- 1 June 1997
- Vol. 59, S28-32
Physiologic role and diuretic efficacy of atrial natriuretic peptide in health and chronic renal disease.
In recent years, different clinical studies have provided new information on the pathophysiological role and diuretic effectiveness of atrial natriuretic peptide (ANP) in subjects with normal renal function and patients with chronic renal disease. Plasma ANP (pANP) was increased by infusion at the lowest doses ever tested in humans who were on low salt diet to the levels that the same subjects gained when on a normal salt diet; ANP accounted for at least 40% of the increase of natriuresis. Similarly, ANP appeared to be mainly involved in the physiological down-regulation of salt excretion (that is, during the shift from a normal to low-sodium diet). Interestingly, data have been also attained on the efficacy of ANP as diuretic agent when administered at a low nonhypotensive dosage in normals as well as CRF patients. Indeed, low-dose ANP promoted a marked increase of sodium excretion in CRF patients to the same levels observed in normals, likely because the renal patients exhibited a more marked pANP increment secondary to the lower renal catabolism of the infused hormone. Moreover, aldosterone suppression was greater in CRF patients with respect to normals. Furthermore, the fractional urinary excretion of cGMP increased more in CRF patients than in normals. Finally, ANP infusion augmented the urinary losses of the main solutes retained in CRF (urea, potassium, phosphorous) with a significant decrease in the plasma levels. Hence, ANP per se not only plays a significant role in the up- and down-regulation of sodium excretion in healthy state and chronic renal disease, but it may also be considered to be a powerful and unique diuretic agent in CRF at nonhypotensive dosages.
- 1 March 1991
- Vol. 51 (3) , 734-6
Acute effects of low-dose cyclosporine on renal function in normal subjects.
- 1 March 1991
- Vol. 51 (3) , 734-6
Acute effects of low-dose cyclosporine on renal function in normal subjects.
- 1 June 1988
- Vol. 20, 563-7
Dopamine counteracts the acute renal effects of cyclosporine in normal subjects.
- 1 June 1988
- Vol. 20, 563-7
Dopamine counteracts the acute renal effects of cyclosporine in normal subjects.
- 1 January 1987
- Vol. 39 (1) , 89-92
[Efficacy of the combination aztreonam + ampicillin in the treatment of peritonitis during continuous ambulatory peritoneal dialysis].
- 1 January 1987
- Vol. 39 (1) , 89-92
[Efficacy of the combination aztreonam + ampicillin in the treatment of peritonitis during continuous ambulatory peritoneal dialysis].
- 1 July 1986
- Vol. 38 (3) , 313-6
[Tubular changes after urographic examination. A histopathologic study of 52 cases].
- 1 July 1986
- Vol. 38 (3) , 313-6
[Tubular changes after urographic examination. A histopathologic study of 52 cases].
- 1 January 1983
- Vol. 19, 744-8
Why diuretic treatment increases azotaemia in patients with chronic glomerulonephritis.
- 1 January 1983
- Vol. 19, 744-8
Why diuretic treatment increases azotaemia in patients with chronic glomerulonephritis.